



HERBAL SUPPLEMENTS *and the* BRAIN

UNDERSTANDING THEIR
HEALTH BENEFITS AND HAZARDS

S.J. ENNA



STATIA NORTON

Praise for Herbal Supplements and the Brain

“Both skeptics and believers in the value of herbal supplements for brain conditions will enjoy the calm objective analysis to which these two experienced pharmacologists put the most popular products. You may not like their conclusions, but their evidence is convincing.”

—**Floyd E. Bloom**, MD, Professor Emeritus, Molecular and Integrative Neuroscience Department, TSRI

“Written with authority yet as lucid and enticing as a novel, the Enna/Norton book is certainly the finest volume I know addressing the interface of herbs, the brain, and behavior. It will be of value and fun for the educated layperson as well as the professional.”

—**Solomon H. Snyder**, M.D., Department of Neuroscience, Johns Hopkins University School of Medicine

“It all began with Adam’s apple. Knowing what you add to your diet may change your life. Getting a kick from a cup of coffee, fighting depression with St. John’s wort, drifting away with valerian, or reaching a ripe old age with Gingko, this book gives insights into the pros and cons of taking herbal supplements. Excellent and entertaining reading!”

—**Hanns Möhler**, Professor of Pharmacology, University of Zurich, Switzerland

“If you are someone who takes and believes in herbal supplements, then this book is a must-read for you. I’ll bet you will be surprised at some of the information. It is written by two extraordinarily qualified authors, who have decades of experience with the effects and toxicities of drugs and supplements. The aim of the book is to use proven criteria to evaluate if herbal supplements are effective or not. This information is not always easy to find, so read on.”

—**Michael J Kuhar, Ph.D.**, Yerkes National Primate Research Center of Emory University, Candler Professor of Neuropharmacology, School of Medicine, Georgia Research Alliance Eminent Scholar, Center for Ethics of Emory University

This page intentionally left blank

Herbal Supplements and the Brain

This page intentionally left blank

Herbal Supplements and the Brain

**Understanding Their Health
Benefits and Hazards**

**S. J. Enna
Stata Norton**

Illustrated by Kevin S. Smith

Vice President, Publisher: Tim Moore
Associate Publisher and Director of Marketing: Amy Neidlinger
Editorial Assistant: Pamela Boland
Development Editor: Russ Hall
Operations Specialist: Jodi Kemper
Assistant Marketing Manager: Megan Graue
Cover Designer: Chuti Prasertsith
Managing Editor: Kristy Hart
Project Editor: Anne Goebel
Copy Editor: Geneil Breeze
Proofreader: Debbie Williams
Indexer: Erika Millen
Compositor: Nonie Ratcliff
Manufacturing Buyer: Dan Uhrig

© 2012 by Pearson Education, Inc.
Publishing as FT Press
Upper Saddle River, New Jersey 07458

FT Press offers excellent discounts on this book when ordered in quantity for bulk purchases or special sales. For more information, please contact U.S. Corporate and Government Sales, 1-800-382-3419, corpsales@pearsontechgroup.com. For sales outside the U.S., please contact International Sales at international@pearson.com.

Company and product names mentioned herein are the trademarks or registered trademarks of their respective owners.

All rights reserved. No part of this book may be reproduced, in any form or by any means, without permission in writing from the publisher.

Printed in the United States of America

First Printing May 2012 with corrections May 2013

ISBN-10: 0-13-282497-3

ISBN-13: 978-0-13-282497-2

Pearson Education LTD.

Pearson Education Australia PTY, Limited.

Pearson Education Singapore, Pte. Ltd.

Pearson Education Asia, Ltd.

Pearson Education Canada, Ltd.

Pearson Educación de Mexico, S.A. de C.V.

Pearson Education—Japan

Pearson Education Malaysia, Pte. Ltd.

Library of Congress Cataloging-in-Publication Data

Enna, S. J.

Herbal supplements and the brain : understanding their health benefits and hazards /
S.J. Enna, Stata Norton.

p. cm.

Includes bibliographical references and index.

ISBN 978-0-13-282497-2 (hardback : alk. paper) 1. Herbs—Therapeutic use. 2. Alternative medicine. 3. Dietary supplements—Therapeutic use. I. Norton, Stata, 1922- II. Title.

RM666.H33E55 2013

615.3'21—dc23

2012006286

We thank our spouses, Colleen Enna and David Ringle, for the decades they have devoted to encouraging us to pursue our scientific interests and career goals. Neither this book, nor any of our other accomplishments, would have been possible without their patience, support, and understanding. This work is dedicated to them.

This page intentionally left blank

Contents

	Preface	xvi
Chapter 1	The Gifts of Eden	1
Chapter 2	Transforming Plants into Gold	7
	Prehistoric Evidence	8
	Early Documentation	9
	Western Culture	11
	Alchemy	13
	Chemistry	15
Chapter 3	Thinking Like a Pharmacologist	17
	The Origins of Pharmacology	19
	Pharmacodynamics	21
	Pharmacokinetics	24
	In Vitro and In Vivo Studies	27
	Pharmacology and Herbal Supplements	27
	Herbal Supplement Pharmacology Checklist	28
Chapter 4	The Brain as a Drug Target	33
	The Human Brain	36
	Chemical Neurotransmission	39
	Neurotransmitter Systems	41
	Behavioral Assays	45
	Clinical Studies	49
Chapter 5	Ginkgo (Ginkgo biloba)	53
	Botany	55
	Therapeutic Uses	55
	Constituents	57
	Pharmacokinetics	59
	Pharmacodynamics	61
	Adverse Effects	65
	Pharmacological Perspective	66

Chapter 6	St. John's Wort (<i>Hypericum perforatum</i>)	67
	Botany	69
	Therapeutic Uses	70
	Constituents	71
	Pharmacokinetics	74
	Pharmacodynamics	75
	Adverse Effects	80
	Pharmacological Perspective	81
Chapter 7	Valerian (<i>Valeriana officinalis</i>)	83
	Botany	84
	Therapeutic Uses	85
	Constituents	86
	Pharmacokinetics	88
	Pharmacodynamics	90
	Adverse Effects	93
	Pharmacological Perspective	94
Chapter 8	Lemon Balm (<i>Melissa officinalis</i>)	97
	Botany	98
	Therapeutic Uses	99
	Constituents	99
	Pharmacokinetics	100
	Pharmacodynamics	102
	Adverse Effects	106
	Pharmacological Perspective	106
Chapter 9	Kava (<i>Piper methysticum</i>)	109
	Botany	110
	Therapeutic Uses	111
	Constituents	112
	Pharmacokinetics	112
	Pharmacodynamics	114
	Adverse Effects	118
	Pharmacological Perspective	120

Chapter 10	Lavender (<i>Lavandula angustifolia</i>)	123
	Botany	124
	Therapeutic Uses	125
	Constituents	126
	Pharmacokinetics	127
	Pharmacodynamics	129
	Adverse Effects	134
	Pharmacological Perspective	135
Chapter 11	Kudzu (<i>Pueraria lobata</i>)	137
	Botany	138
	Therapeutic Uses	139
	Constituents	140
	Pharmacokinetics	141
	Pharmacodynamics	143
	Adverse Effects	146
	Pharmacological Perspective	147
Chapter 12	Daffodil (<i>Narcissus pseudonarcissus</i>)	149
	Botany	151
	Therapeutic Uses	152
	Constituents	153
	Pharmacokinetics	154
	Pharmacodynamics	155
	Adverse Effects	158
	Pharmacological Perspective	159
Chapter 13	Passion Flower (<i>Passiflora incarnata</i>)	161
	Botany	162
	Therapeutic Uses	163
	Constituents	164
	Pharmacokinetics	166
	Pharmacodynamics	168
	Adverse Effects	173
	Pharmacological Perspective	173

Chapter 14	Coffee, Tea, and Cocoa	175
	Botany	177
	Therapeutic Uses	178
	Constituents	180
	Pharmacokinetics	182
	Pharmacodynamics	184
	Adverse Effects	186
	Pharmacological Perspective	187
Chapter 15	Epilogue	189
	Endnotes	195
	Index	237

Acknowledgments

We thank Mr. Kirk Jensen, Mr. Russ Hall, and their colleagues at Pearson for their guidance and assistance in creating this volume. Thanks, too, to Mr. Kevin S. Smith for preparing the illustrations and for contributing his creative talents to this project. We are particularly grateful to Ms. Lynn LeCount at the University of Kansas Medical School for her editorial and technical assistance. Without her efforts, this work would not have been possible.

About the Authors

A Kansas City native, **S. J. Enna** received his undergraduate education at Rockhurst University and his M.S. and Ph.D. degrees in pharmacology from the University of Missouri. Following postdoctoral work at the University of Texas Southwestern Medical School in Dallas, F. Hoffmann-LaRoche in Basel, Switzerland, and Johns Hopkins University Medical School, Dr. Enna joined the faculty at the University of Texas Medical School in Houston in the departments of Pharmacology and of Neurobiology and Anatomy. In 1986, Dr. Enna was appointed Scientific Director of Nova Pharmaceutical Corporation in Baltimore. At this time, he also held appointments as a Lecturer in Neuroscience at Johns Hopkins Medical School and Adjunct Professor of Pharmacology at Tulane Medical School in New Orleans. Dr. Enna returned to Kansas City in 1992 as Professor and Chair of Pharmacology at the University of Kansas Medical Center, where he is currently Associate Dean for Research and Graduate Education, and Professor of Pharmacology and of Physiology. Dr. Enna has published nearly 300 research reports, reviews, and book chapters describing his research, and has edited or coedited 30 books on various subjects relating to neuropharmacology. For decades, he has served as a scientific consultant for most of the major pharmaceutical companies and as a board member on government panels and private research foundations. He has been appointed to the editorial boards of numerous pharmacology journals and has served as editor of leading journals in the field, including the *Journal of Pharmacology and Experimental Therapeutics*.

At present, Dr. Enna is editor of *Biochemical Pharmacology and Pharmacology and Therapeutics*, coeditor of *Current Protocols in Pharmacology*, and series editor of *Advances in Pharmacology*. Dr. Enna has held many elective offices in professional societies, including the presidency of the American Society for Pharmacology and Experimental Therapeutics. Currently, he is Secretary-General of the International Union of Basic and Clinical Pharmacology. He has received numerous awards in recognition of his contributions to the discipline of pharmacology. Among these are two Research Career

Development Awards from the National Institutes of Health, the John Jacob Abel and Torald Sollmann Awards from the American Society for Pharmacology and Experimental Therapeutics, the Daniel H. Efron Award from the American College of Neuropsychopharmacology, and the PhRMA Foundation Excellence Award from the Pharmaceutical Manufacturer's Association Foundation. Dr. Enna is internationally recognized for his research in neuropharmacology, especially his contributions in characterizing the biochemical and pharmacological properties of neurotransmitter receptors in general, and the γ -aminobutyric acid (GABA) system in particular.

Dr. Stata Norton received her B.S. degree in Biology from the University of Connecticut, Storrs, her Master's degree in Zoology from Columbia University in New York, and her Ph.D. degree in Zoology and Physiological Chemistry from the University of Wisconsin in Madison. After working for over a decade as a neuropharmacologist at the Wellcome Research Laboratories in Tuckahoe, New York, in 1962, she accepted a faculty appointment in Department of Pharmacology, Toxicology, and Therapeutics at the University of Kansas Medical School in Kansas City. While at the University of Kansas, she also served as Professor of Dietetics and Nutrition, Dean of the School of Allied Health, and Professor at the Institute for Cell Biology in Valencia, Spain. Since 1990, she has been Emeritus Professor of Pharmacology at the University of Kansas Medical School.

Dr. Norton was the recipient of a Research Scientist Award from the National Institute of Mental Health and was elected to Outstanding Educators of America in 1975. She served on the Editorial Advisory boards for *Psychopharmacology*, *Neurotoxicology*, and *Toxicology and Industrial Health*. She was President of the Central States Chapter of the Society of Toxicology and a member of the Pre-clinical Psychopharmacology Study Section of the National Institute of Mental Health. She has published more than 150 scientific research articles and reviews in scientific journals and books. Her main research interests are the development of quantitative methods for analyzing animal behavior and the characterization of the effects of chemicals on behavior. For more than two decades, she authored a major review on the toxic effects of plants for the reference work *Toxicology: The Basic Science of Poisons*.

Preface

While for more than 200,000 years humans have been consuming plant materials, such as flowers, fruits, leaves, and roots, for therapeutic benefit, it is only in the last 150 years that scientists have been able to isolate, identify, examine, and categorize the biologically active constituents in plants. Many of the compounds identified, or chemical derivatives of them, are now employed as drugs. The ability to obtain such precise scientific information, and to synthesize other active compounds, opened the way for legislators in the early twentieth century to enact laws regulating the marketing and sale of chemicals for therapeutic purposes. The creation of these regulatory requirements was spurred by the fact that many inert, and sometimes toxic, products were sold as medications to the public. Current laws mandate that any substance marketed as a treatment for a particular condition must first undergo rigorous testing in laboratory animals and humans to demonstrate its safety and effectiveness.

Although prescription and over-the-counter medications are subject to tight federal oversight, there are few regulations concerning the sale of herbal supplements. In the United States, the chief requirement is that no formal claims be made of any therapeutic benefit resulting from the use of these products. Nonetheless, consumers are continuously exposed in the lay press and online to reports on the purported curative properties of certain herbs or how their consumption can help prevent disease. Such reports are no doubt responsible for driving sales in this multibillion dollar industry. However, like our ancient ancestors, today's consumer may be purchasing and consuming these products for health benefits based solely on the word of others, not as a result of an independent and objective analysis of the data supporting the claims. This is understandable, as most lack the technical background for making an informed scientific judgment. The aim of this book is to address this need.

Herbal products are used around the world for a variety of purposes. Among these is the treatment of central nervous system disorders, such as anxiety, insomnia, alcoholism, dementia, and depression. Herbal supplements are also taken to modify brain function in the

treatment of other conditions, such as chronic pain and obesity. Because some of the symptoms of these disorders resolve over time without medication, and many have a strong psychological component, it is often difficult to prove the efficacy of an herbal product as a treatment for these conditions. That is, while the effectiveness of a dietary supplement that reduces body weight would be apparent, the contribution of an herbal product in lessening feelings of depression, or in enhancing cognitive abilities, is more difficult to quantify. For this reason, the claims for such benefits may not be supported by experimental data. In this regard, the consumer may be no different than the primitive who ingested a plant material to alter his mental status. Sometimes it worked; often it did not. A change in perception or feelings, or in sleep patterns, could be the result of an active constituent in the plant, or the power of suggestion. Prolonged consumption of any product with no inherent value is not only costly, but potentially dangerous as anything taken into the body can have toxic consequences. This volume is devoted to a discussion of herbal supplements taken to affect brain function because of the unique challenges associated with assessing the effectiveness of such products.


Written for the nonscientist, the book is informally divided into two parts. The first section, chapters 1–4, provides an historical perspective on the use of plant products to modify central nervous system function and on the development of the techniques employed for drug discovery. Included is a discussion of the basic principles of pharmacology, the science of drugs, as they relate to assessing the potential effectiveness and safety of an herbal supplement. Descriptions are provided of the components of the central nervous system that are dysfunctional in neurological and psychiatric disorders, and the targets of drugs used to treat these conditions. Taking all of these issues into consideration, a short checklist is provided to assist the potential consumer in determining, from a scientific standpoint, whether a particular product is likely to contain chemicals that beneficially affect brain function. The reader is encouraged to complete the first four chapters before proceeding to those describing individual plant products. The introductory chapters provide the context, concepts, and definitions essential for understanding fully the reasoning and conclusions drawn in the second part of the book.

Chapters 5 through 15 are devoted to a scientific assessment of the claims made for a select group of herbal products that are believed to have central nervous system effects. The pharmacological principles provided in the earlier chapters are applied in this analysis, with the checklist items used to guide the reader in the search for the truth. In this way, the reader can appreciate how answering a few key questions yields powerful insights into the potential benefit of these products.

The primary audience for this book is consumers interested in determining the value of herbal products purported to influence brain function. Others who will find this information of interest and value are students considering careers in the neurosciences or drug discovery, and scientists seeking an updated review of this field. By having the tools needed to make an objective and scientific assessment of these products, consumers are in a much better position to maximize the benefits of herbal supplements. This information will also make it possible to minimize the risks to one's health that comes with consuming these substances without adequate information on their effectiveness and safety.

1

The Gifts of Eden



Adam wasn't hungry and was apprehensive about the potential consequences of eating the forbidden fruit. He was, however, convinced the plant material could provide benefits beyond its nutritional value. On the one hand, God told him that its consumption would be fatal, while the serpent contended the plant would impart new knowledge. Both were right. After eating the fruit Adam lost his home and immortality, and was made aware of the concepts of good and evil. He would need this new knowledge to survive in the world outside of Eden.

Besides its allegorical importance for Jews, Christians, and Muslims, this biblical account provides lessons for those interested in the therapeutic benefits of herbal supplements, also known as nutritional, dietary, or food supplements. Defined as a product that contains a vitamin, mineral, herb or other botanical, an amino acid, an extract, or any combination of these materials, the United States government considers dietary supplements to be foods rather than drugs. This has

significant implications with regard to their regulation and the assurances provided to consumers. Because of this categorization, potential users must obtain on their own objective data about these products. The aim of this book is to provide such information.

The most fundamental question pertaining to dietary supplements is whether there is any evidence that they provide benefits beyond possible nutritional value. Written some 2,500 years ago, the Genesis account of Adam's introduction to these products indicates that humans have been familiar with the possible mystical and therapeutic powers of plants for quite some time. Moreover, the Old Testament account demonstrates that then, as now, there was uncertainty, and therefore risk, associated with the consumption of plants and plant products for religious, therapeutic, or, as in Adam's case, educational purposes.

The fruit consumed by Adam is unknown. In Old English, the word "apple" is simply a synonym for fruit. Regardless, when tempted to eat the plant product, Adam was at a distinct disadvantage to today's consumer. There was no historical record on its possible effects and no scientific data on its safety. Moreover, as the basic principles of pharmacology, the science of drugs, had not yet been established, he was unable to assess these properties himself. Rather, Adam had to rely solely on the word of others.

The constraints experienced by Adam remained for thousands of years until written records were maintained on the medicinal value of plants. More centuries passed before chemists were able to identify, and pharmacologists objectively study, the therapeutically active constituents in plant and animal products. Only during the past century has research revealed the diseases and disorders that are most responsive to these constituents, and to define precisely the appropriate doses to maximize safety and effectiveness in most individuals.

Anecdotal accounts about the potential benefits of dietary supplements have existed for thousands of years. Evidence includes pollen grains found on Neanderthal (*Homo neanderthalensis*) graves that were from plants lacking showy flowers, such as the yarrow (*Achillea millefolium*). It is inferred that these plants were placed there not for adornment, but to provide the departed a supply of medications in the afterlife.¹ This concept is based, in part, on the fact that many of the plants deposited on Neanderthal gravesites were

subsequently described as therapeutics in early medical books, indicating that word of their therapeutic powers was passed on for millennia. For example, yarrow is mentioned in the Assyrian Herbal (800 BC), one of the oldest listings of therapeutically active plant products,² as well as in the Ebers papyrus (1500 BC) from Egypt. The Greek poet Homer described in *The Iliad* (800 BC) the use of yarrow to cure wounds, as did the Roman naturalist Pliny the Elder in his writings during the first century AD.³

A conservative estimate is that plants have been used as therapeutics at least since the appearance of modern man, some 200,000 years ago. It seems reasonable that as early humans foraged for food they would accidentally discover the curative powers of some plants or take note of the fact that consumption of a certain type of seed, root, or fruit produced discernable effects on mood, sensory input, or alleviated general aches and pains. Indeed, as a species, humans are indebted to the many thousands of forgotten ancestors who became ill or died in the process of identifying plants and animals suitable for consumption. Thus, through trial and error, early man was able to identify plants that possess useful medicinal properties.

In addition to using plants to cure disease, they were also consumed in the ongoing quest for immortality. Recipes for “elixirs of life” were described in ancient writings. An example is the *Epic of Gilgamesh*, the story of a Sumarian hero that was recorded in 2000 BC.⁴ After many travails, Gilgamesh obtained the plant of immortality from deep in the sea. Unfortunately for Gilgamesh, the plant was subsequently stolen by a serpent. This tale has many of the features of the biblical account of Adam and Eve. In the end, Gilgamesh returned home to Sumer to, like the rest of us, spend the remainder of his days as a mortal, awaiting the inevitable.

As in Genesis, ancient medical texts demonstrate that plant products have been used for therapeutic purposes for millennia. During most of this time no concerted effort was made to understand the reason for their effectiveness, or, in modern terminology, their mechanism of action. The first recorded attempts to synthesize therapeutics were made by European alchemists during the Middle Ages.⁵ Besides their efforts to transform base metals into gold, the alchemists were interested in what made substances therapeutically

useful as they wanted the power to transform basic materials into drugs. They were hindered in this quest, however, by the prevailing theories about the nature of matter and the causes of disease.

From the time of Aristotle to the seventeenth century, the use of plants in European medicine was based on the idea that all nature was composed of four basic elements: earth, air, fire, and water. Disease resulted from an imbalance of bodily humors. It was believed this imbalance could be countered by one or more of the four plant classes—cold, dry, hot, and wet—that corresponded to the four basic elements of nature. Mixtures of plants, usually from the same class, were preferred over a single specimen for treating medical conditions. For example, combinations of “cold” plants were used to treat fevers. Given these theories, drug discovery remained an empirical enterprise for thousands of years, with the identification of active plants and plant products left solely to chance.

By the seventeenth century, belief in the Aristotelian four elements was being challenged, most notably by the Irish chemist Robert Boyle.⁶ Boyle understood that the precise identification and classification of the basic elements of nature were absolutely essential for understanding the universe, including drug actions. Thanks to his efforts, and those of many others, modern chemistry emerged in the nineteenth century. This made it possible to isolate, chemically define, and study the biological responses to plant constituents. As a result of these efforts, drugs were identified in plants that were first discovered by our distant ancestors. Many of these compounds, or their chemical derivatives, are still used today.

Given the historical records, and contemporary scientific data, there is no question that plants produce an abundance of substances that provide benefits beyond their nutritional value. However, not all plant constituents have been isolated and properly tested for effectiveness, and, unlike drugs, there is no government requirement that a manufacturer demonstrate effectiveness before marketing an herbal supplement. Like Adam, the consumer must rely on the word of others about the benefits of these products.

This book is designed to address this issue by providing basic information needed to assess the potential therapeutic value of plant products. Included are fundamental principles of pharmacology and

about how drugs and natural products can affect various organs and organ systems. Explanations and examples are provided about what determines whether an ingested substance will find its way into the bloodstream, and then to the targeted site in the body at a concentration sufficient to have a beneficial effect. Other topics include the ways in which natural products may influence the blood levels of other substances, including drugs, and the likelihood that such interactions may diminish the effectiveness of prescription medications or alter normal body chemistry. While the principles described apply to all dietary supplements and drugs, emphasis is placed on factors that relate especially to herbal supplements purported to influence brain function. Individual chapters are devoted to a discussion of selected nutritional supplements that are said to enhance memory, or to aid in the treatment of depression, anxiety, insomnia, and alcoholism. These products were chosen because the promised benefits can be difficult to quantify and are more subject to influence by the power of persuasion than is the case with other therapeutics. This is why the use of such substances has been exploited over the centuries by shamans to maintain their social standing, and by charlatans for monetary gain. The properties of these products are described in the context of the basic principles of pharmacology and the results of scientific studies, both human and laboratory animal, aimed at determining effectiveness and mechanism of action. The approach taken in objectively evaluating these products can be used by the reader as a guide for assessing the information available on any dietary supplement. This work is intended for those who are curious about the potential benefits and risks associated with the use of food supplements. The information provided will be of particular value for individuals who, like Adam, are interested in how drugs and natural products affect us for good and evil.

This page intentionally left blank

Index

A

- acetaldehyde, 145
- acetoxyvaleric acid, 89
- acetylcholine, 22, 42-44
- acetylcholine neurotransmission, effects of lavender (*Lavandula angustifolia*) on, 133
- acetylcholine nicotinic receptor system, 155
- acetylcholinesterase, 103, 133-134, 155-156
- acetylsalicylic acid (aspirin), 21
- Achillea millefolium* (yarrow)
 - presence in Neanderthal graves, 2, 8
 - use in Greco-Roman era, 3
- adenosine, 42-43, 185
- Adlumia fungosa*, 43
- adverse effects
 - of cocoa (*Theobroma cacao*), 186-187
 - of coffee (*Coffea arabica*), 186-187
 - of daffodil (*Narcissus pseudonarcissus*), 158-159
 - of ginkgo (*Ginkgo biloba*), 65-66
 - of kava (*Piper methysticum*), 118-120
 - of kudzu (*Pueraria lobata*), 146-147
 - of lavender (*Lavandula angustifolia*), 134-135
 - of lemon balm (*Melissa officinalis*), 106
 - of passion flower (*Passiflora incarnata*), 173
 - of St. John's wort (*Hypericum perforatum*), 80-81
 - of tea (*Camellia sinensis*), 186-187
 - of *Valeriana officinalis* (Valerian), 93-94
- aglycones, 140-142
- agonists, 23
- alchemy, 3-4, 13-15
- alcohol withdrawal, therapeutic use of kudzu (*Pueraria lobata*) for, 143-146
- alcoholism, therapeutic use of kudzu (*Pueraria lobata*) for, 143-146
- aldehyde dehydrogenase-2, 144-145

alkaloids, 192-193

caffeine

- adverse effects*, 186-187
- chemical structure of*, 181
- historical use of*, 175-177
- pharmacodynamics*, 184-186
- pharmacokinetics*, 182-184
- pharmacological perspective*, 187-188
- therapeutic uses*, 178-180

definition of, 149

in daffodil. *See* daffodil

(Narcissus pseudonarcissus)

in passion flower (Passiflora incarnata), 164

theobromine, 180-181

- adverse effects*, 186-187
 - pharmacodynamics*, 184-186
 - pharmacokinetics*, 182-184
 - pharmacological perspective*, 187-188
 - therapeutic uses*, 179
- theophylline, 180-181
- adverse effects*, 186-187
 - pharmacodynamics*, 184-186
 - pharmacokinetics*, 182-184
 - pharmacological perspective*, 187-188
 - therapeutic uses*, 179

alpha-pinene, 73

alprazolam, interaction with St. John's wort, 80

Althea, presence in Neanderthal graves, 8

Alzheimer's disease, 37, 47

Neuropsychiatric Inventory and Alzheimer's Disease

Assessment Scale, 50

therapeutic use of ginkgo (Ginkgo biloba), 64

therapeutic use of lemon balm (Melissa officinalis), 103

therapeutic use of lavender (Lavandula angustifolia), 130-132

therapeutic use of galantamine, 155-157

Amaryllidaceae, 151-153

amitriptyline, interaction with St. John's wort, 80

amphetamine, 46, 191

amygdala, 37

analgesia, therapeutic use of lavender (Lavandula angustifolia) for, 130-131

analgesic effect

- of daffodil (Narcissus pseudonarcissus), 156
- of passion flower (Passiflora incarnata), 171

Andrea (Jesuatti Friar), 21

Andrea, Giovanni, 14

anecdotal reports, 49

Anethum graveolens (dill seed), 12

animal test models, 46-48

antagonists, 23

anthrones, 72

anti-inflammatory effect

- of daffodil (Narcissus pseudonarcissus), 157
- of passion flower (Passiflora incarnata), 172

anticonvulsant effect
 of lavender (*Lavandula angustifolia*), 130
 of passion flower extract, 170
 antimicrobial properties of
 lavender (*Lavandula angustifolia*), 131
 antioxidant activity of lemon balm (*Melissa officinalis*), 104
 antitumor activity of
 daffodil (*Narcissus pseudonarcissus*), 157
 anxiety
 therapeutic use of kava (*Piper methysticum*), 116-117
 therapeutic use of lemon balm (*Melissa officinalis*), 102-105
 therapeutic use of lavender (*Lavandula angustifolia*), 129-134
 therapeutic use of passion flower (*Passiflora incarnata*), 168-170
 therapeutic use of Valerian (*Valeriana officinalis*), 90-93
 apigenin, 164-169
 apolinaris (*Hyoscyamus*), 13
 apoptosis, effect of ginkgo (*Ginkgo biloba*) on, 62
 Aristotle, 12
 aromatase, 172
 Ascyrum (St. Peter's wort), 70
 aspirin (acetylsalicylic acid), 21
 assays, behavioral, 45-48
 Assyrian Herbal, 3, 10-11
Atropa belladonna, 23
 awaine, 118
 axo-axonic synapses, 40
 axo-dendritic synapses, 40
 axons, 36

B

Bacon, Francis, 15
 barbiturates, 43, 83
 behavioral assays, 45-48
Ben Cao Pin Hui Jing Yao (Liu Wen-Tai), 54-55
 benzodiazepines, 43, 83
 beta-amyloid, 47, 103
 beta-caryophyllene, 73
 beta-myrcene, 73
 bianthraquinone, 72
 Biblical mention of herbal supplements, 1
 bicuculline, 43
 bilobalide, 58-60
 bioavailability, 24-26, 59-60
 bornyl acetate, 87-88
 botany
 of cocoa (*Theobroma cacao*), 177-178
 of coffee (*Coffea arabica*), 177-178
 of daffodil (*Narcissus pseudonarcissus*), 151-152
 of ginkgo (*Ginkgo biloba*), 55
 of kava (*Piper methysticum*), 110-111
 of kudzu (*Pueraria lobata*), 138-139
 of lavender (*Lavandula angustifolia*), 124-125
 of lemon balm (*Melissa officinalis*), 98
 of passion flower (*Passiflora incarnata*), 162-163
 of St. John's wort (*Hypericum perforatum*), 69-70
 of tea (*Camellia sinensis*), 177-178

of Valerian (*Valeriana officinalis*), 84-85

Boyle, Robert, 4, 15

brain

chemical neurotransmission, 39-41
 neurotransmitter systems, 41-45
 nucleus accumbens, 114
 sigma receptors, 77
 structure of, 36-39

C

caffeic acid, 182

caffeine

adverse effects, 186-187
 chemical structure of, 181
 historical use of, 175-177
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 178-180

Camellia japonica, 177-179

Camellia sinensis (tea), 11

adverse effects, 186-187
 botany, 177-178
 constituents, 180-182
 historical use of, 175-177
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 178-180

camphor, 126

cannabinoids, 191

Cannabis, 191

Cannabis sativa, 11, 191

catechins, 182-185

categorization of herbal supplements, 1, 18

Catha edulis, 190

caudate nucleus, 38

Celsus, 12

Centaurea (century plant), 8

central nervous system, 33-35.
See also brain

central nervous system
 depressants, 83

central nervous system
 disorders, 34

century plant (*Centaurea*), 8

cerebellum, 37-38

cerebral cortex, 37-38

challenges of pharmacological
 analysis of herbal supplements,
 27-28

chemical neurotransmission,
 39-41

chemistry, development of, 4,
 15-16

chlordiazepoxide (*Librium*®), 83

chlorogenic acid, 182

chocolate. *See* cocoa

chrysin, 164-169, 172

cingulate cortex, 37

Cistus laudanifer, 20

citral, 99-104

citronellal, 99-104

Clark, A. J., 24

clinical depression, 67

clinical studies, 49-51

clovamide, 182

Clusiaceae, 69

cocaine, 191

cocoa (*Theobroma cacao*)

adverse effects, 186-187

botany, 177-178

constituents, 180-182

historical use of, 175-177

pharmacodynamics, 184-186

pharmacokinetics, 182-184

- pharmacological perspective, 187-188
 - therapeutic uses, 178-180
 - codeine, 190
 - Coffea arabica** (coffee)
 - adverse effects, 186-187
 - botany, 177-178
 - constituents, 180-182
 - historical use of, 175-177
 - pharmacodynamics, 184-186
 - pharmacokinetics, 182-184
 - pharmacological perspective, 187-188
 - therapeutic uses, 178-180
 - Coffea canephora**, 175
 - coffee (*Coffea arabica*)
 - adverse effects, 186-187
 - botany, 177-178
 - constituents, 180-182
 - historical use of, 175-177
 - pharmacodynamics, 184-186
 - pharmacokinetics, 182-184
 - pharmacological perspective, 187-188
 - therapeutic uses, 178-180
 - Commiphora myrrha**, 9
 - Cook, James, 109
 - Corey, Elias James, 57
 - corpus striatum, 38
 - Crataeus, 12
 - crossover studies, 49
 - Culpepper, Nicholas, 124
 - cyclosporine, interaction with St. John's wort, 80
 - cytochrome P450 enzymes, 26
- D**
- daffodil (*Narcissus pseudonarcissus*), 149-151
 - adverse effects, 158-159
 - botany, 151-152
 - constituents, 153-154
 - historical use of, 152
 - pharmacodynamics, 155-158
 - pharmacokinetics, 154-155
 - pharmacological perspective, 159
 - therapeutic uses, 152
 - daidzein, 140-142, 146
 - daidzin, 140, 144
 - Darwin, Charles, 109
 - De Medicina (Celsus), 12
 - dehydrogenase, 145
 - delta-9-tetrahydrocannabinol, 191
 - dementia. *See*
 - Alzheimer's disease
 - dendrites, 36
 - depression, therapeutic use of St. John's wort for, 67-71, 75-80
 - desmethoxyyangonin, 112-114, 120
 - dextromethorphan, interaction with St. John's wort, 80
 - Dian Nan Ben Cao* (Lan Mao), 54
 - diazepam (Valium®), 43, 83, 89
 - Dicentra cucullaria* (Dutchman's britches), 43
 - Dietary Supplement Health and Education Act of 1994, 18
 - diffusion, 25
 - Digenea simplex*, 43
 - digoxin
 - interaction with lemon balm (*Melissa officinalis*), 101
 - interaction with St. John's wort (*Hypericum perforatum*), 80
 - dihydrokavain, 112-114
 - dihydromethysticin, 112-114, 120

dill seed (*Anethum graveolens*), 12
donepezil, 156
dopamine, 36, 42-44
double-blind studies, 49
Dr. Willmar Schwabe GmbH & Company, 57, 132
drug receptors, discovery of, 22-24
Dutchman's britches (*Dicentra cucullaria*), 43

E

early documentation of herbal supplements, 3, 9-11
Ebers papyrus, 3, 9
Ebers, George, 9
EGb 761, 57
Ehrlich, Paul, 22
elements, periodic table of, 16
elevated plus maze, 46
emetic effect of
 daffodil (*Narcissus pseudonarcissus*), 157
endocannabinoids, 191
endogenous depression, 67
English lavender. *See* lavender (*Lavandula angustifolia*)
Enquiry into Plants (Theophrastus), 151
enterovirus 71, 157
enzymes
 acetylcholinesterase, 133, 155-156
 aldehyde dehydrogenase-2, 144-145
 aromatase, 172
 cytochrome P450 enzymes, 26
 5-lipoxygenase, 77

 nitric oxide synthase, 77
 phosphodiesterase, 184
Ephedra, 11
 Ephedra equisetina, 190
 Ephedra sinica, 190
 presence in Neanderthal graves, 8
ephedrine, 8, 190-191
Epic of Gilgamesh, 3
epigallocatechin-3-gallate, 182, 185-187
Erythroxyton coca, 191
ethanol, 83
ethyl alcohol, 83
excitatory neurotransmitters, 40
extrapyramidal system, 38

F

FDA (Food and Drug Administration)
 establishment of, 17
 lack of oversight over herbal supplements, 18-19
 role of, 17-18
Federal Food, Drug, and Cosmetic Act, 17
fennel (*Foeniculum vulgare*), 12
5-lipoxygenase, 77
flavokawain B, 118-119
flavonoids
 bioavailability of, 59-60
 in cocoa (*Theobroma cacao*), 182
 in coffee (*Coffea arabica*), 182
 in ginkgo standardized extract, 58
 in kudzu (*Pueraria lobata*), 140-141

in passion flower (*Passiflora incarnata*), 164-168
 in tea (*Camellia sinensis*), 182
 flavonol glycosides in ginkgo standardized extract, 58-60
 flavonols in St. John's wort, 73, 77
 fluoxetine (Prozac®), 75, 116
Foeniculum vulgare (fennel), 12
 Food and Drug Administration. *See* FDA (Food and Drug Administration)
 Forester, Johann, 109
 four basic elements of nature (Aristotle), 12
 French lavender (*Lavandula stoechas*), 123-124
 French spikenard (*Valeriana celtica*), 84

G

GABA (γ -aminobutyric acid), 42, 171
 GABA receptors, 90-91
 GABA transaminase, 102
 galantamine, 152-159
 adverse effects, 158-159
 anti-inflammatory activity, 157
 chemical structure of, 153
 therapeutic use for Alzheimer's disease, 155-157
 pharmacodynamics, 155-156
 pharmacokinetics, 154-155
 galanthine, 153
Galanthus woronowi, 152
 Galen, 84
 γ -aminobutyric acid (GABA), 42
 Ge Gen. *See* kudzu (*Pueraria lobata*)

GEM (Ginkgo Evaluation of Memory) study, 64
 genistein, 140-142, 146
 genistin, 140
 geranial, 99
 Gerard, John, 12, 70, 99, 125, 151-152
 ginkgo (*Ginkgo biloba*)
 adverse effects, 65-66
 botany, 55
 constituents, 57-59
 historical use of, 53-54
 pharmacodynamics, 61-65
 pharmacokinetics, 59-61
 pharmacological perspective, 66
 popularity of, 53
 standardized extract, 58-59
 therapeutic uses, 55-57
 Ginkgo Evaluation of Memory (GEM) study, 64
 Ginkgoaceae, 53
 ginkgolide B, 57-58
 Ginkgophyla, 53
 Giovanni Andrea (friar), 124
 glia, 36
globus pallidus, 38
 glutamic acid, 42
 Glycininae, 139
 glycitein, 142
 glycosides in kudzu (*Pueraria lobata*), 140-143
 government oversight of herbal supplements, lack of, 18-19
 Graminae, 151
 Greco-Roman era, herbal supplements in, 3, 11-13
 growth of herbal supplement market, 18
 Gymnosperm, 55

H

- haemanthamine, 153
- half-life, 25
- haloperidol, 46
- hangover, effectiveness of kudzu (*Pueraria lobata*) for, 145
- harmaline, 164
- harmalol, 164
- harmene, 164
- harmol, 164
- Hatshepsut, 10
- hepatotoxicity associated with kava (*Piper methysticum*), 118-119
- herbal supplement pharmacology checklist, 28-32
- heroin, 190
- hippocampus, 37
- Hippocrates, 11, 84
- historical development of pharmacology, 19-21
- historical use of herbal supplements
 - alchemy, 3-4, 13-15
 - Biblical mention of herbal supplements, 1
 - chemistry, 4, 15-16
 - cocoa (*Theobroma cacao*), 175-177
 - coffee (*Coffea arabica*), 175-177
 - early documentation, 3, 9-11
 - ginkgo (*Ginkgo biloba*), 53-54
 - Greco-Roman era, 3, 11-13
 - kava (*Piper methysticum*), 109-110
 - kudzu (*Pueraria lobata*), 137-138
 - lavender (*Lavandula angustifolia*), 123-124
 - lemon balm (*Melissa officinalis*), 97-98
 - passion flower (*Passiflora incarnata*), 161-162
 - prehistoric evidence, 2, 8
 - St. John's wort (*Hypericum perforatum*), 67-69
 - tea (*Camellia sinensis*), 175-177
 - Valerian (*Valeriana officinalis*), 83-84
- HMS Beagle*, 109
- HMS Endeavour*, 109
- Homer, 3, 9
- homoorientin, 164-166
- hydrophilic compounds, 24
- hydroxylated phenylpropionic acid, 101
- hydroxyvalerenic acid, 89
- hyoscyamine, 23
- Hyoscyamus (*apolaris*), 11-13
- Hyoscyamus *niger*, 23
- hyperforin, 72-73, 76
- hypericin, 71-72, 76
- hypericins, 72
- Hypericum attenuatum*, 69
- Hypericum maculatum*, 69
- Hypericum perforatum* (St. John's wort)
 - adverse effects, 80-81
 - botany, 69-70
 - constituents, 71-74
 - historical use of, 67-69
 - pharmacodynamics, 75-80
 - pharmacokinetics, 74-75
 - pharmacological perspective, 81-82
 - therapeutic uses, 70-71
- hypothalamus, 37

I

- Ilex paraguariensis* (maté), 177
- The Iliad* (Homer), 3, 9
- in vitro studies, 27
- in vivo studies, 27
- inhibitory neurotransmitters, 40
- insomnia, therapeutic use of
 - Valerian (*Valeriana officinalis*) for, 93
- ironwort (*Sideritis heraclea*), 13
- isoflavones in kudzu (*Pueraria lobata*), 140-143
- isoorientin, 164
- isorhamnetin in ginkgo
 - standardized extract, 58
- isoschaftoside, 164-165
- isovaleric acid, 87
- isovitexin, 164-166

J-K

- kaempferol
 - in ginkgo standardized extract, 58
 - in St. John's wort, 73, 77
- kainic acid, 43
- kava (*Piper methysticum*)
 - adverse effects, 118-120
 - botany, 110-111
 - constituents, 112
 - historical use of, 109-110
 - pharmacodynamics, 114-117
 - pharmacokinetics, 112-114
 - pharmacological perspective, 120-121
 - therapeutic uses, 111
- kavain, 112-114
- kavalactones, 112-119
- ketamine, 43
- kew. *See* ginkgo (*Ginkgo biloba*)

- kudzu (*Pueraria lobata*)
 - adverse effects, 146-147
 - botany, 138-139
 - constituents, 140-141
 - historical use of, 137-138
 - pharmacodynamics, 143-146
 - pharmacokinetics, 141-143
 - pharmacological perspective, 147-148
 - therapeutic uses, 139-140

L

- Labiatae, 98
- Lamiaceae, 98, 124
- Lan Mao, 54
- Langley, John, 22
- large scale clinical trials, 49
- laudanum, 20
- Lavandula angustifolia* (lavender)
 - adverse effects, 134-135
 - botany, 124-125
 - constituents, 126-127
 - historical use of, 123-124
 - pharmacodynamics, 129-134
 - pharmacokinetics, 127-129
 - pharmacological perspective, 135-136
 - therapeutic uses, 125-126
- Lavandula latifolia* (spike lavender), 123-124
- Lavandula stoechas* (French lavender), 123-124
- Lavandula x intermedia*, 124
- lavandulin, 125
- lavender (*Lavandula angustifolia*)
 - adverse effects, 134-135
 - botany, 124-125
 - constituents, 126-127
 - historical use of, 123-124

pharmacodynamics, 129-134
 pharmacokinetics, 127-129
 pharmacological perspective,
 135-136
 therapeutic uses, 125-126
legislation
 Dietary Supplement Health and
 Education Act of 1994, 18
 Federal Food, Drug, and
 Cosmetic Act, 17
 United States Pure Food and
 Drug Act, 17
Leguminosae, 139
lemon balm (*Melissa officinalis*)
 adverse effects, 106
 botany, 98
 constituents, 99-100
 historical use of, 97-98
 pharmacodynamics, 102-105
 pharmacokinetics, 100-102
 pharmacological perspective,
 106-107
 therapeutic uses, 99
Li Shih-Chen, 54-55, 139
Librium® (chlordiazepoxide), 83
Liliaceae, 151
 limbic system, 37-38
 linalool, 126-131
 linalyl acetate, 126-128, 131
 linalyl acetate, 126
Linnaeus, Carl, 97
 lipid peroxidation, 104
 lipophilic compounds, 24
Liu Wen-Tai, 54
 liver toxicity associated with kava
 (*Piper methysticum*), 118-119
Loganiaceae, 23
London Pharmacopeia, 125
 lorazepam, 132

luteolin, 167-168
 lycorine, 153-154, 157-158
Lycoris (spider lily), 153

M

Ma Huang, 190
 maidenhair. *See* ginkgo
 (*Ginkgo biloba*)
 major depression, 67
 malaria, historical use of *St.*
John's wort for, 70
 maltol, 164
Mandragora, 11
Manerix®, 75
MAO (monoamine oxidase)
 inhibition by kava, 116
 marijuana, 191-192
 maté (*Ilex paraguariensis*), 177
 maypop. *See* passion flower
 (*Passiflora incarnata*)
Medicina Antiqua, 70
 medulla, 37
 megaleion, 9
**Melissa officinalis (lemon
 balm)**, 11
 adverse effects, 106
 botany, 98
 constituents, 99-100
 historical use of, 97-98
 pharmacodynamics, 102-105
 pharmacokinetics, 100-102
 pharmacological perspective,
 106-107
 therapeutic uses, 99
memory
 scopolamine-induced memory
 impairment, 48
 therapeutic use of ginkgo
 (*ginkgo biloba*) for, 64

- Mendeleev, Dmitri, 16, 20
 mendeleium, 16
 mercuries (alchemy), 15
 meta-coumaric acid, 101
 methylxanthine alkaloids
 adverse effects, 186-187
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective,
 187-188
 therapeutic uses, 178-180
 methysticin, 112-114
 Mithridates, King of Pontus, 12
 mithridatum, 12, 124
 Moclobemide, 75
*The Mode of Action of Drugs on
 Cells* (Clark), 24
Modern Herbal (Grieve), 125
 monoamine oxidase (MAO)
 inhibition by kava, 116
 Monocotyledonae, 151
 monoterpenes
 in lemon balm (*Melissa
 officinalis*), 99
 in lavender (*Lavandula
 angustifolia*), 126
 Morpheus, 20
 morphine, 20, 70, 190
 Morris water maze assay, 47
 Muscari, presence in
 Neanderthal graves, 8
 myrrh, 9-10
- N**
- naphthodianthrone, 72
Narcissus poeticus, 151
Narcissus pseudonarcissus
 (daffodil), 149-151
 adverse effects, 158-159
 botany, 151-152
 constituents, 153-154
 historical use of, 152
 pharmacodynamics, 155-158
 pharmacokinetics, 154-155
 pharmacological
 perspective, 159
 therapeutic uses, 152
Narcissus serotinus, 151
Nardostachys jatamansi
 (spikenard), 84
 nardus. *See* lavender (*Lavandula
 angustifolia*)
 National Formulary, 164
Natural History (Pliny), 97
 Neanderthal use of herbal
 supplements, 2, 8
 neopallium, 37
 neral, 99
 neurokinin, 158
 neurons, 36
 neuropharmacology
 behavioral assays, 45-48
 brain structure, 36-39
 chemical neurotransmission,
 39-41
 clinical studies, 49-51
 definition of, 35
 neurotransmitter systems, 41-45
 Neuropsychiatric Inventory and
 Alzheimer's Disease
 Assessment Scale, 50
 neurotransmission
 acetylcholine, 44
 adenosine, 43
 dopamine, 44
 explained, 39-41
 GABA (γ -aminobutyric acid), 42
 glutamic acid, 42
 neurotransmitter systems, 36,
 41-45
 serotonin, 44

NF-kappaB inhibition by
 kava, 116
 nitric oxide, 77
 nitric oxide synthase, 77
 norepinephrine, 75, 190
 Norpramin® (desipramine), 116
*Novum Organum, or New
 Method* (Bacon), 15
 nucleus accumbens, 37, 114

O

oleanolic acid, 99-101
 1,8-cineole, 126-127
 open-label clinical trials, 49
 opium, 20-21
 opium poppy, 190
 orientin, 164-167
 oxygen radicals, 185

P

PAF (platelet-activating
 factor), 63
 paleopallium, 37
 Papaver somniferum, 11, 20,
 70, 190
 Papaveraceae, 43
 Paracelsus, 14, 20
 Parkinson's disease, 39
 Passiflora incarnata (passion
 flower)
 adverse effects, 173
 botany, 162-163
 constituents, 164-165
 historical use of, 161-162
 pharmacodynamics, 168-172
 pharmacokinetics, 166-168
 pharmacological perspective,
 173-174
 therapeutic uses, 163-164
 Passiflora lutea, 162
 Passifloraceae, 162
 passion flower (*Passiflora
 incarnata*)
 adverse effects, 173
 botany, 162-163
 constituents, 164-165
 historical use of, 161-162
 pharmacodynamics, 168-172
 pharmacokinetics, 166-168
 pharmacological perspective,
 173-174
 therapeutic uses, 163-164
 passive diffusion, 25
Pen Ts'ao Kang Mu (Li Shih-
 Chen), 54
 Peonia, 11
 peptides, 158
 Periodic Table of Elements,
 development of, 16, 20
 pharmacodynamics
 challenges of assessing herbal
 supplements, 27-28
 of cocoa (*Theobroma cacao*),
 184-186
 of coffee (*Coffea arabica*),
 184-186
 of daffodil (*Narcissus
 pseudonarcissus*), 155-158
 development of, 22-23
 drug receptors, discovery of,
 22-24
 explained, 21-24
 of ginkgo (*Ginkgo biloba*), 61-65
 of kava (*Piper methysticum*),
 114-117
 of kudzu (*Pueraria lobata*),
 143-146
 of lavender (*Lavandula
 angustifolia*), 129-134

- of lemon balm (*Melissa officinalis*), 102-105
- of passion flower (*Passiflora incarnata*), 168-172
- pharmacology checklist for herbal supplements, 28-32
- of plant alkaloids, 192-193
- of St. John's wort (*Hypericum perforatum*), 75-80
- of tea (*Camellia sinensis*), 184-186
- of *Valeriana officinalis* (Valerian), 90-93
- pharmacokinetics**
 - bioavailability, 24-26
 - challenges of assessing herbal supplements, 27-28
 - of cocoa (*Theobroma cacao*), 182, 184
 - of coffee (*Coffea arabica*), 182-184
 - of daffodil (*Narcissus pseudonarcissus*), 154-155
 - explained, 24-27
 - of ginkgo (*Ginkgo biloba*), 59-61
 - half-life, 26
 - of kava (*Piper methysticum*), 112-114
 - of kudzu (*Pueraria lobata*), 141-143
 - of lavender (*Lavandula angustifolia*), 127-129
 - of lemon balm (*Melissa officinalis*), 100-102
 - of passion flower (*Passiflora incarnata*), 166-168
 - of plant alkaloids, 192-193
 - of tea (*Camellia sinensis*), 182-184
 - of *Valeriana officinalis* (Valerian), 88-90
- pharmacology checklist for herbal supplements, 28-32
- of St. John's wort (*Hypericum perforatum*), 74-75
- pharmacology checklist for herbal supplements, 28-32
- phenobarbital, 43, 83
- phosphodiesterase, 184
- phytoestrogens, 141, 146
- Piper methysticum** (kava)
 - adverse effects, 118-120
 - botany, 110-111
 - constituents, 112
 - historical use of, 109-110
 - pharmacodynamics, 114-117
 - pharmacokinetics, 112-114
 - pharmacological perspective, 120-121
 - therapeutic uses, 111
- Piper nigrum**, 110
- Piper wickmanni**, 110
- Piperaceae**, 110
- pipermethystine, 118
- placebos, 51
- platelet-activating factor (PAF), 63
- Pliny, 68, 97, 152
- Pliny the Elder, 3
- plus maze test, 92
- polyphenols, 181
- pons, 37
- postsynaptic neurons, 40
- prefrontal cortex, 37
- prehistoric evidence of herbal supplement use, 2, 8
- presynaptic receptors, 40
- primary motor area (cerebral cortex), 38

proteins
 beta amyloid, 47
 transporter proteins, 25-26
 Prozac® (fluoxetine), 75, 116
 Psuedo-Apuleius, 13
 psychiatric disorders, therapeutic
 use of ginkgo (*Ginkgo biloba*)
 for, 64
 psychotherapeutics, challenges in
 testing, 50-51
Pueraria chinensis, 139
Pueraria lobata (kudzu)
 adverse effects, 146-147
 botany, 138-139
 constituents, 140-141
 historical use of, 137-138
 pharmacodynamics, 143-146
 pharmacokinetics, 141-143
 pharmacological perspective,
 147-148
 therapeutic uses, 139-140
Pueraria montana, 139
 puerarin, 140-146
 purple passion flower. *See*
 passion flower (*Passiflora*
incarnata)
 putamen, 38
 pyriform cortex, 37

Q-R

quercetin
 in ginkgo standardized
 extract, 58
 in St. John's wort, 73, 77
 receptors, discovery of, 22-24
 regulation of herbal
 supplements, lack of, 18-19
 Rhazes, 14
 rivastigmine, 156

Rome, historical use of herbal
 supplements, 3, 11-13
 rosmarinic acid, 99-103
 rosuvastatin, interaction with
 lemon balm (*Melissa*
officinalis), 101
 Rubiaceae, 178

S

salicin, purification of, 21
 salicylic acid, 21
Salix spp., 21
 salts (alchemy), 15
The Sceptical Chymist
 (Boyle), 15
 schaftoside, 164-165
 sciatica, historical use of St.
 John's wort for, 70
 scopolamine-induced memory
 impairment, 48
 Senecio, presence in
 Neanderthal graves, 8
 sensory cortex, 38
 septum, 37
 serotonin, 36, 42-44, 75
 sertraline, 79
 Serturmer, Freidrich, 20
 sesquiterpenes, 87-90
Shen Nong Ben Cao Jing, 54
 side effects. *See* adverse effects
Sideritis heraclea (ironwort), 13
 sigma receptors, 77
 silexan, 132
 6,7-epoxy-linalool, 128
 Solanaceae, 10
 spider lily (*Lycoris*), 153
 spike lavender (*Lavandula*
latifolia), 123-124
 spikenard (*Nardostachys*
jatamansi), 84

squill (*Urgenia maritima*), 13
St. John's wort (*Hypericum perforatum*), 74-75
 adverse effects, 80-81
 botany, 69-70
 constituents, 71-74
 historical use of, 67-69
 pharmacodynamics, 75-80
 pharmacokinetics, 74
 pharmacological perspective, 81-82
 therapeutic uses, 70-71
St. Peter's wort (*Ascyrum*), 70
standardized extract of ginkgo (*Ginkgo biloba*), 58
Strychnos, 23
substantia nigra, 38
sulfurs (alchemy), 15
swertisin, 164
swertismarin, 165
symptom scales, 50
synapses, 36
synaptic cleft, 36

T

$t_{1/2}$ (half life), 26
tacrine, 156
tannins in St. John's wort, 73
tea (*Camellia sinensis*)
 adverse effects, 186-187
 botany, 177-178
 constituents, 180-182
 historical use of, 175-177
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 178-180

tectoridin, 144
terpene trilactones in ginkgo standardized extract, 58-60, 63-64
thalamus, 37-38
Theobroma cacao (cocoa)
 adverse effects, 186-187
 botany, 177-178
 constituents, 180-182
 historical use of, 175-177
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 178-180
theobromine, 180-181
 adverse effects, 186-187
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 179
Theophrastus, 9, 97, 151
theophylline, 180-181
 adverse effects, 186-187
 pharmacodynamics, 184-186
 pharmacokinetics, 182-184
 pharmacological perspective, 187-188
 therapeutic uses, 179
thiopental, 83
Tincture of Opium, 20
transient receptor potential channels (TRPC), 76
transmitters
 acetylcholine, 44
 adenosine, 43
 dopamine, 44
 explained, 39-41
 GABA (γ -aminobutyric acid), 42

glutamic acid, 42
 neurotransmission, 40
 serotonin, 44

transporter proteins, 25-26

trigonelline, 182

triterpenes in lemon balm
 (*Melissa officinalis*), 99

TRPC (transient receptor
 potential channels), 76

U

United States Food and Drug
 Administration. *See* FDA (Food
 and Drug Administration)

United States National
 Formulary, 164

United States Pure Food and
 Drug Act, 17

Urgenia maritima (squill), 13

ursolic acid, 99-101

V

valepotriates, 87-90

valeric acid, 88-92

Valerian (*Valeriana officinalis*)

adverse effects, 93-94

botany, 84-85

constituents, 86-88

historical use of, 83-84

pharmacodynamics, 90-93

pharmacokinetics, 88-90

pharmacological perspective,
 94-95

therapeutic uses, 85-86

valerian epoxy triesters, 87

Valeriana, 11

Valeriana celtica (French
 spikenard), 84

Valeriana ciliata, 85

Valeriana officinalis (Valerian)

adverse effects, 93-94

botany, 84-85

constituents, 86-88

historical use of, 83-84

pharmacodynamics, 90-93

pharmacokinetics, 88-90

pharmacological perspective,
 94-95

therapeutic uses, 85-86

Valeriana pauciflora, 85

Valeriana septentrionalis, 85

Valeriana uliginosa, 85

Valerianaceae, 84

Valium® (diazepam), 43, 83

vesicles, 40

vestibular nuclei, 38

vitexin, 164-166

W-X-Y-Z

wild apricot. *See* passion flower
 (*Passiflora incarnata*)

willow bark extract, 21

yangonin, 112-114

yarrow (*Achillea millefolium*)

presence in Neanderthal graves,
 2, 8

use in Greco-Roman era, 3

yellow passion flower (*Passiflora
 lutea*), 162

This page intentionally left blank



The life sciences revolution is transforming
our world as profoundly as the industrial
and information revolutions did
in the last two centuries.

FT Press Science will capture the excitement and
promise of the new life sciences, bringing breakthrough
knowledge to every professional and interested citizen.

We will publish tomorrow's indispensable work in
genetics, evolution, neuroscience, medicine,
biotech, environmental science, and whatever
new fields emerge next.

We hope to help you make sense of the future,
so you can *live* it, *profit* from it, and *lead* it.